Momentum Stock Watch: LA Jolla Pharma (LJPC)
- Sunday, August 16, 2020, 22:09
- Stock Market, Stock Research
- Add a comment
Company Profile: |
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload. The company was founded in 1989 and is headquartered in San Diego, California. |
Recent News: |
On July 28, 2020, the company announced the closing of La Jolla’s acquisition of Tetraphase. La Jolla acquired Tetraphase for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value rights (CVRs). For the three and six months ended June 30, 2020, U.S. net sales of GIAPREZA were $5.8 million and $13.4 million, up 2% and 33%, respectively, from the same periods in 2019. La Jolla’s net loss for the three and six months ended June 30, 2020 was $15.6 million and $24.2 million, or $0.57 and $0.89 per share, respectively, compared to $30.4 million and $62.1 million, or $1.12 per share and $2.29 per share, respectively, for the same periods in 2019. |
|
|
Fundamental Analysis: |
Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency. |
Growth – Measures the growth of both the company’s income statement and cash flow. @@@@@ |
Profitability – Measures the historical price movement of the stock. @@@@@ |
Solvency – Measures the solvency of the company based on several ratios. @@@@@ |
Efficiency – Measures the strength and historic growth of a company’s return on invested capital. @@@@@ |
Conclusion: |
LJPC’s strengths can be seen in its strong growth and robust profitability compared with its peers. Technical indicators signal the bullish signs, as there is a bullish crossover in MACD and Stochastic oscillator, the RSI stands at 45.48 with positive bias. We rate LA Jolla Pharma (LJPC) a STRONG BUY. |
About the Author
Write a Comment
Gravatars are small images that can show your personality. You can get your gravatar for free today!
You must be logged in to post a comment.